JMA Campaigns To Support Public Coverage For Vaccinations
This article was originally published in PharmAsia News
Japan's most influential physician's lobbying group, Japan Medical Association plans to launch a nationwide campaign to urge earlier public coverage for vaccinations such as haemophilus influenzae type B vaccine
You may also be interested in...
The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.
Ability to quickly scale manufacturing is a key criteria for Operation Warp Speed therapeutics, but for monoclonal antibodies the most effective approach may mean fewer doses. FDA’s Janet Woodcock said the government is supporting a range of antibody approaches for COVID-19 so that if virus escape mutants emerge from single antibody treatment there will be other options, while Regeneron argues the cocktail approach is safer, even though it will likely mean fewer doses of drug will be available.
German sickness insurance funds are under unusual financial pressure as a result of the COVID-19 pandemic. And a recent decision to reduce reimbursement for COVID-19 confirmatory tests by one third has left testing labs and diagnostics makers frustrated. See what Martin Walger, chief executive of the German diagnostic industry association (VDGH) said about it here.